XZP 3621
Alternative Names: XZP-3621Latest Information Update: 04 May 2023
At a glance
- Originator Xuanzhu Biopharmaceutical
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Preclinical Cancer
Most Recent Events
- 01 May 2023 Xuanzhu Biopharmaceutical plans a pharmacokinetics phase I trial (In healthy volunteers, In adults) in China (PO) in May 2023 (NCT05836805)
- 19 Oct 2022 Xuanzhu Biopharmaceutical plans a phase I trial in healthy subjects in China (PO) (NCT05586568)
- 05 Aug 2022 Xuanzhu Biopharmaceutical plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent) in China (PO) (NCT05482087)